ARCH ONCOLOGY
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
ARCH ONCOLOGY
Social Links:
Industry:
Biotechnology Medical Oncology Therapeutics
Founded:
2006-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Website Url:
http://www.archoncology.com
Total Employee:
11+
Status:
Active
Contact:
(314)932-4032
Email Addresses:
[email protected]
Total Funding:
250.4 M USD
Technology used in webpage:
Euro SPF Google Maps Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Cloudflare DNS GoDaddy
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a gene-edited cell therapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Arch Oncology
Avego Healthcare Capital
Avego Healthcare Capital investment in Series C - Arch Oncology
Broadfin Capital
Broadfin Capital investment in Series C - Arch Oncology
Lightchain
Lightchain investment in Series C - Arch Oncology
3×5 Partners
3×5 Partners investment in Series C - Arch Oncology
RiverVest
RiverVest investment in Series C - Arch Oncology
FMB Research
FMB Research investment in Series C - Arch Oncology
Adage Capital Management
Adage Capital Management investment in Series C - Arch Oncology
Eventide
Eventide investment in Series C - Arch Oncology
Roche Venture Fund
Roche Venture Fund investment in Series C - Arch Oncology
Official Site Inspections
http://www.archoncology.com
- Host name: 106.233.71.198.host.secureserver.net
- IP address: 198.71.233.106
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Arch Oncology"
Arch Oncology - Crunchbase Company Profile & Funding
Arch Oncology is a venture-stage biopharmaceutical company. View contacts for Arch Oncology to access new leads and connect with decision-makers. Formerly Known as Vasculox. Arch …See details»
Arch Oncology - LinkedIn
Arch Oncology | 2,341 followers on LinkedIn. Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class …See details»
Arch Oncology - Overview, News & Similar companies - ZoomInfo
May 22, 2021 · Arch Oncology, Inc., a Brisbane, Calif. and St. Louis, MO-based clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic …See details»
Arch Oncology Presents New Preclinical T-ALL Data on Highly ...
BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody …See details»
Arch Oncology Strengthens Medical and Clinical Leadership …
LOUIS, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, …See details»
BioGenerator Company Arch Oncology Closes $105M Series C …
LOUIS, April 27, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, …See details»
Arch Oncology Strengthens Medical and Clinical Leadership
LOUIS, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, …See details»
Arch Oncology Raises $50 Million Series B Financing
Mar 25, 2019 · BRISBANE, Calif. and ST. LOUIS-- ( BUSINESS WIRE )--Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best …See details»
Arch Oncology Appoints Laurence Blumberg, M.D. President and …
LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody …See details»
Arch Oncology Announces Two New Preclinical Data
LOUIS, March 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody …See details»
Arch Oncology Appoints Laurence Blumberg, M.D. President and …
Apr 7, 2021 · BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc, a clinical-stage immuno-oncology company focused on the discovery and …See details»
Arch Oncology Advances Anti-CD47 Antibody AO-176 into …
Oct 5, 2020 · AO-176 is an anti-CD47 antibody with a potential best-in-class profile that works by blocking the “don’t eat me” signal and also by directly killing tumor cells, with preferential …See details»
Arch Oncology Receives U.S. FDA Orphan Drug Designation for
LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, …See details»
Arch Oncology Receives U.S. FDA Orphan Drug Designation for …
Jan 21, 2022 · Arch Oncology, Inc. is a privately held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the …See details»
Arch Oncology Secures $105 Million Series C Financing - Yahoo …
LOUIS, April 27, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, …See details»
Arch Oncology to Present New Preclinical Data on Highly …
Nov 9, 2020 · Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the …See details»
Arch Oncology Advances Anti-CD47 Antibody AO-176 into …
Oct 5, 2020 · Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the expansion …See details»
Arch Oncology Secures $105 Million Series C Financing
Apr 27, 2021 · Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the …See details»
Arch Oncology Presents New Preclinical T-ALL Data on
Apr 10, 2021 · Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the …See details»
Arch Oncology Advances Anti-CD47 Antibody AO-176 into
Oct 5, 2020 · AO-176 is an anti-CD47 antibody with a potential best-in-class profile that works by blocking the “don’t eat me” signal and also by directly killing tumor cells, with preferential …See details»